levofloxacin; imipenem/cilastitin
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Nosocomial Pneumonia
Conditions
Nosocomial Pneumonia
Trial Timeline
Dec 1, 1997 → Jun 1, 2001
NCT ID
NCT00236834About levofloxacin; imipenem/cilastitin
levofloxacin; imipenem/cilastitin is a phase 3 stage product being developed by Johnson & Johnson for Nosocomial Pneumonia. The current trial status is completed. This product is registered under clinical trial identifier NCT00236834. Target conditions include Nosocomial Pneumonia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00236834 | Phase 3 | Completed |
Competing Products
7 competing products in Nosocomial Pneumonia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ceftazidime-avibactam | AbbVie | Phase 1 | 33 |
| Ceftolozane/Tazobactam | Merck | Phase 1 | 33 |
| vancomycin monotherapy + daptomycin monotherapy | Novartis | Phase 3 | 77 |
| linezolid | Pfizer | Phase 3 | 76 |
| C Group + E Group | Pfizer | Phase 2/3 | 64 |
| ceftazidim-avibactam (CAZ-AVI, experimental product) + meropenem (active comparator) | Pfizer | Phase 3 | 76 |
| Veronate | Bristol Myers Squibb | Pre-clinical | 22 |